Huntington Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Huntington Disease Market Outlook

Thelansis’s “Huntington Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Huntington Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Huntington Disease Overview

Huntington's disease, a rare genetic neurodegenerative condition, inflicts devastating consequences on multiple generations of affected families. Its primary hallmark is the progressive deterioration of the putamen, caudate nucleus, and cerebral cortex neurons. The selective breakdown of enkephalin-containing medium spiny neurons within the basal ganglia's indirect pathway is responsible for the characteristic chorea. In contrast, the loss of substance-P-containing medium spiny neurons in the direct pathway leads to dystonia and akinesia. The specific regional pattern of neuronal loss in the cortex and basal ganglia among affected individuals may account for the variations in their clinical presentation. Typically, Huntington's disease emerges between the ages of 30 and 50, with a median life expectancy of approximately 15 years following diagnosis. Although an exceptionally rare juvenile form exists, the usual onset occurs in early middle age, marked by abnormal movements, notably chorea, and psychiatric symptoms like psychosis, depression, and obsessive-compulsive disorder, often accompanied by progressive cognitive decline. As a result, Huntington's disease is considered in the differential diagnosis of conditions involving dementia, chorea, and psychiatric disturbances. Regrettably, there is no cure for Huntington's disease, and its course typically spans 15 to 20 years. The length of the CAG repeats indicates the symptom onset and predicts the age at which an individual may succumb to the disease. Larger CAG repeat sizes correlate with more rapid deterioration in motor, cognitive, and functional abilities. However, the progression of behavioral symptoms is not associated with CAG repeat size. Homozygous individuals with fully penetrant Huntington's disease tend to experience a similar onset age to heterozygotes but may face a faster disease progression. Huntington's disease carries numerous complications:

1. Individuals with dystonia and swallowing difficulties often experience accelerated complications and a shorter lifespan.
2. Chorea with larger amplitude can lead to injuries, improper positioning, fractures, and head trauma.
3. Common causes of death are complications arising from immobility, such as pneumonia, cardiac disease, or infections.
4. Tragically, 25% of patients attempt suicide.
5. Severe behavioral issues can profoundly disable individuals, causing distress to patients, their families, and caregivers.

There is no cure for Huntington's disease (HD) that can halt or reverse its progression, and treatment options are available to alleviate some of its symptoms. Specifically, drugs like tetrabenazine, valbenazine, and deuterabenazine have effectively managed the chorea associated with HD. These medications can help reduce involuntary movements and improve the quality of life for individuals with HD.

• In the United States, the estimated prevalence of Huntington's disease is approximately 12.7 cases per 100,000 people.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: